|
Myocardial Infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48) was a multinational randomized trial of the oral factor Xa inhibitor edoxaban in patients with atrial fibrillation and a CHADS<sub>2</sub> score ≥2.
|
30586727 |
2019 |
|
Myocardial Infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the ENGAGE AF-TIMI 48 trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48), 19,679 patients with atrial fibrillation and hypertension were categorized according to average systolic blood pressure (SBP) and diastolic blood pressure (DBP).
|
31352829 |
2019 |
|
Myocardial Infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inhibition of thrombin generation among high-risk ACS patients (biomarker-positive ACS) with the factor Xa inhibitor rivaroxaban may limit ongoing thrombus formation and myocardial necrosis and thereby improve clinical outcomes.
|
29249166 |
2019 |
|
Myocardial Infarction
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The focus of this review is to compare and contrast potential differences between factor IIa- and factor Xa inhibition with respect to risk of myocardial infarction and to detail underlying mechanisms.
|
30321554 |
2019 |
|
Myocardial Infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
Event rates will be compared with event rates reported in the PREvention oF thromboembolic events-European Registry in Atrial Fibrillation in atrial fibrillation (PREFER in AF) and PREFER in AF Prolongation registries, and in the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation - Thrombolysis in Myocardial Infarction 48 study datasets.
|
30540648 |
2019 |
|
Myocardial Infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
The factor Xa inhibitor rivaroxaban reduces cardiac dysfunction in a mouse model of myocardial infarction.
|
29843086 |
2018 |
|
Myocardial Infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
The ENGAGE AF-TIMI 48 trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction) compared higher-dose edoxaban regimen (HD-ER) and lower-dose edoxaban regimen with well-managed warfarin in 21 105 patients with atrial fibrillation.
|
29748353 |
2018 |
|
Myocardial Infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
The global ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation Atrial Fibrillation-Thrombolysis In Myocardial Infarction 48) trial compared the efficacy and safety of edoxaban versus warfarin over a median follow-up of 2.8 years.
|
30236308 |
2018 |
|
Myocardial Infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48) trial, clinical outcomes of patients with atrial fibrillation with and without HF were examined by baseline digoxin use during a median follow-up of 2.8 years.
|
28666993 |
2017 |
|
Myocardial Infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
In ENGAGE AF-TIMI 48 trial (Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48), the factor Xa inhibitor edoxaban was noninferior to warfarin in preventing stroke or systemic embolic events and significantly reduced bleeding and cardiovascular mortality.
|
28077507 |
2017 |
|
Myocardial Infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
The ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48) Trial compared edoxaban with warfarin with respect to the prevention of stroke or systemic embolism in atrial fibrillation.
|
28862934 |
2017 |
|
Myocardial Infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
All patients with factor I (FI), factor II (FII), factor V (FV), factor VII (FVII), factor X (FX), factor XI (FXI), or factor XIII (FXIII) deficiency or abnormality reported to have presented a myocardial infarction or another acute coronary syndrome were investigated.
|
25155499 |
2015 |
|
Myocardial Infarction
|
0.100 |
Biomarker
|
disease |
LHGDN |
Coagulation factor Xa stimulates interleukin-8 release in endothelial cells and mononuclear leukocytes: implications in acute myocardial infarction.
|
15550696 |
2005 |